Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.

Abstract

PurposeThis meta-analysis aimed to assess the efficacy and safety of cyclin-dependent kinase (CDK) 4/6 inhibitors plus endocrine therapy (ET) in hormonal receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).MethodsWe searched PubMed, Embase, Cochrane, ClinicalTrials.gov., ASCO, ESMO and AACR databases from inception to October 10, 2019 for randomized controlled trials (RCTs) that compared CDK 4/6 inhibitors plus ET to single-agent ET with no treatment-line restriction. The main outcomes analyzed were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and adverse events (AEs).ResultsOf 938 identified studies, 9 RCTs with 5043 women were eligible and included. Compared with ET alone, CDK 4/6 inhibitors and ET combination improved in PFS (hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.50–0.59, p< 0.00001) and OS (HR 0.77, 95% CI 0.69–0.85, p< 0.00001), regardless of ET strategies (HR 0.54, 95% CI 0.50–0.59 in PFS; HR 0.77, 95% CI 0.69–0.85 in OS), treatment line of advanced disease (HR 0.52, 95% CI 0.46–0.59 in PFS; HR 0.75, 95% CI 0.66–0.85 in OS) and menopausal status (HR 0.54, 95% CI 0.50–0.58 in PFS; HR 0.76, 95% CI 0.68–0.84 in OS). Higher risk of grade 3/4 AEs (RR 2.66, 95% CI 2.44–2.90, p < 0.00001) were observed in the combination group than in the ET group.ConclusionsCombination therapy with CDK 4/6 inhibitors and ET prolongs survival in HR+/ HER2- ABC. This combination is a better therapeutic strategy than endocrine monotherapy in HR+/HER2- ABC, regardless of treatment line, menopausal status and other individual characteristics.